
Share
Streamline Targeted LNP Development to Improve Preclinical Translation
Lipid nanoparticles (LNPs) are a leading platform for nucleic acid delivery, but their tendency to accumulate in the liver can limit broader therapeutic applications. Advances in lipid design, surface engineering, and ligand conjugation are enabling targeted LNPs with improved specificity and expanded potential for extrahepatic delivery.
This webinar explores the development of ligand-conjugated LNPs, including strategies for liver de-targeting, modulating protein corona interactions, and reducing ApoE-mediated uptake to achieve more favorable biodistribution.
Panelists discuss formulation optimization and approaches such as covalent conjugation and post-insertion to control ligand incorporation while maintaining nanoparticle stability and performance. The session also examines in vitro models for evaluating receptor binding, cellular uptake, and functional delivery.
Finally, the panel explores preclinical evaluation of targeted LNPs, including the relationship between biodistribution, target expression, and immunogenicity to help guide candidate selection and clinical translation.
Watch the webinar to learn practical strategies for advancing targeted LNPs from formulation through preclinical validation.